- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02623023
Prophylaxis for Anti-VEGF-induced IOP Elevation
Brimonidine/Timolol Fixed Combination Prophylaxis for Intraocular Pressure Elevation Following Intravitreal Injection of Antivascular Endothelial Growth Factor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The recent introduction of antivascular endothelial growth factor (anti-VEGF) agents has quickly progressed to become the standard of care for several ocular diseases. Between 2006 and 2010, anti-VEGF treatment for neovascular age-related macular degeneration (AMD) was initiated in over 620 000 eyes of Medicare beneficiaries in the United States. This paradigm shift in retinal therapy stems from evidence that VEGF regulates angiogenesis and vascular permeability, processes which characterize the pathophysiology of diabetic retinopathy and AMD. Several large multicenter, randomized clinical trials have demonstrated that patients with neovascular AMD and clinically significant macular edema (CSME) benefit from frequent intravitreal anti-VEGF injections, particularly with ranibizumab . Ranibizumab is a humanized monoclonal antibody Fab fragment (IgG1) that inhibits all identified VEGF isoforms, including VEGF165, VEGF121 and VEGF110.
Rigorous study has consistently demonstrated a good relative safety profile for anti-VEGF agents. While transient rise in intraocular pressure (IOP) is a known effect immediately following intravitreal injection (IVI), sustained IOP elevation was not initially reported in patients undergoing anti-VEGF therapy. It was not until post-hoc analysis of the MARINA , ANCHOR AND VIEW trials that a significant long-term effect on IOP from ranibizumab was detected. However, there are increasing reports in the literature documenting this phenomenon.
Bakri et al. reported a case series of ocular hypertension (OHT) (IOP ranging 30 - 50 mm Hg) after 0.05 mL intravitreal ranibizumab, which persisted and required treatment. Kahook et al. published a case series of six patients undergoing anti-VEGF therapy who developed persistent OHT, two of whom had a prior diagnosis of glaucoma/glaucoma suspect. In a larger, retrospective review of 215 patients being treated with IVI by Good et al., 6% of patients required medical or laser treatment for sustained IOP elevation. Subgroup analysis revealed that patients with a history of glaucoma had a substantially higher likelihood of experiencing sustained IOP elevation, despite a lower median number of IVI than the non-glaucoma group. In a retrospective study by Choi et al. , seven of 127 patients (5.5%) developed sustained OHT in the study eye, whereas the fellow eye demonstrated stable IOP. Two other large retrospective series have reported similar incidence of persistent IOP elevation, and review of the literature reveals an incidence of 3.45% to 11.6% in patients with neovascular AMD. Post-hoc analysis of a large, multi-center randomized clinical trial for treatment of diabetic CSME found the ranibizumab group had a 3-fold increased risk of sustained IOP elevation at 3 years compared to the sham-injection group. This study did not enroll patients with a history of glaucoma/glaucoma suspect, thus could not define their risk ratio. A prospective study of 217 eyes undergoing anti-VEGF IVI found that persistent IOP elevation was a frequent outcome, and that the IOP peak was significantly correlated with the number of injections. Further, patients with prior diagnosis of glaucoma/glaucoma suspect had an incidence of 12.9% of sustained OHT, compared with 3.2% in the non-glaucoma subgroup.
The pathogenesis of persistent ocular hypertension has not yet been elucidated, but may be secondary to chemical damage to the trabecular meshwork from the anti-VEGF agents themselves, or mechanically by micro-particle obstruction. Some studies indicate that the number of IVI is an independent risk factor for the development of long-term ocular hypertension , and that patients with pre-existing glaucoma are particularly vulnerable.
Transient IOP elevation following anti-VEGF injection has been noted at 30 minutes post-injection and rarely requires anterior chamber paracentesis for treatment . Though this rise in IOP elevation is expected to return to baseline by 1-hour post-IVI, the long-term consequences of this phenomenon are unknown. One proposed mechanism for this transient effect on IOP is increased volume of intraocular contents after injection . Gismondi et al found a significant relationship between shorter axial length and higher transient IOP following intravitreal ranibizumab. One group designed a randomized controlled trial to evaluate the effect of preventative treatment for this short-term rise in IOP. Brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL) was administered twice a day on the day prior to injection and on the day of treatment, and reduced the rapid increase in post-injection IOP in a safe and effective manner. However, this study did not evaluate the incidence of persistent OHT.
As IOP elevation is strongly linked with the development of glaucoma, this potential outcome in patients undergoing anti-VEGF therapy warrants attention. The data published on this topic to date is primarily comprised of retrospective chart reviews, case series, and post-hoc analysis of the MARINA, ANCHOR and Diabetic Retinopathy Clinical Research Network 2010 and VIEW trials. Many studies reveal inconsistent methodology in terms of IOP measurement and IVI technique. Ultimately, there is no consensus on which factors may predispose patients to the development of iatrogenic IOP elevation following anti-VEGF therapy. Further, prophylactic treatment for sustained OHT has not been prospectively studied.
Currently, there are no guidelines for IOP monitoring in patients undergoing anti-VEGF therapy. Our study aims to define a treatment algorithm for the monitoring and prophylaxis of anti-VEGF-related iatrogenic ocular hypertension. This may also shed some light into the possible mechanism of post-injection IOP spike. Further, our research may help identify a subgroup of patients vulnerable to long-term sequelae as a result of this phenomenon.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Prima Moinul, MD
- Phone Number: 38070 905-573-7777
- Email: prima.moinul@gmail.com
Study Contact Backup
- Name: Sarah J Mullen, MD
- Phone Number: 38260 (905) 573-7777
- Email: sarah.mullen@medportal.ca
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age equal to or greater than 18 years
- Baseline visual acuity between 20/40 and 20/200 in the eye chart score
- Diagnosed with either, CNV secondary to neovascular AMD, CSME secondary to diabetes mellitus (DM), or CSME secondary to retinal vein occlusion (RVO)
Exclusion Criteria:
- Baseline IOP ≥30 mmHg
- Diagnosed with Neovascular glaucoma
- Patients unable to undergo Humphrey 24-2 visual field testing or optical coherence tomography
- Active ocular inflammatory disease including uveitis
- Prior retinal or vitreous surgery including vitrectomy, gas tamponade, silicone oil tamponade or scleral buckling
- Prior surgical management of glaucoma including trabeculectomy or filtering device
- Active hepatitis or clinically significant liver disease
- Clinically significant kidney disease
- History of penetrating injury or severe ocular trauma
- Concurrent enrolment in other clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combigan group
Combigan will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
|
brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
Other Names:
|
Placebo Comparator: Refresh tears
Refresh tears will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
|
This is a placebo group.
Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
long-term intraocular pressure measurements
Time Frame: 6 months
|
long-term IOP measurements in patients receiving serial IVI of 0.5 mg ranibizumab (0.05 mL) with six months follow-up
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Ocular Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Brimonidine Tartrate, Timolol Maleate Drug Combination
Other Study ID Numbers
- PAVE-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
Santen Inc.Completed
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on Combigan
-
Carmel Medical CenterUnknown
-
Vedic Lifesciences Pvt. Ltd.Completed
-
Genovate Biotechnology Co., Ltd.,Allergan MedicalUnknown
-
Seoul National University HospitalUnknownNormal Tension GlaucomaKorea, Republic of
-
EMSCompletedOcular Hypertension | Primary Open-angle GlaucomaBrazil
-
Meir Medical CenterMeir Hospital, Kfar Saba, IsraelUnknownComplications of Diabetes MellitusIsrael
-
Cornerstone Health Care, PAAllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleKorea, Republic of
-
AllerganTerminatedGlaucoma, Angle-ClosureThailand
-
AllerganCompletedOcular Hypertension | GlaucomaChina